دورية أكاديمية
أعرض في EDS

Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

التفاصيل البيبلوغرافية
العنوان: Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.
المؤلفون: Martin HL; School of Medical Sciences, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK., Mounsey RB, Mustafa S, Sathe K, Teismann P
المصدر: Experimental neurology [Exp Neurol] 2012 Jun; Vol. 235 (2), pp. 528-38. Date of Electronic Publication: 2012 Mar 07.
نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0370712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2430 (Electronic) Linking ISSN: 00144886 NLM ISO Abbreviation: Exp Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: Orlando Fl : Academic Press
Original Publication: New York.
مواضيع طبية MeSH: Disease Models, Animal*, Antioxidants/*therapeutic use , PPAR gamma/*agonists , PPAR gamma/*antagonists & inhibitors , Parkinson Disease/*prevention & control, Anilides/pharmacology ; Animals ; Antioxidants/pharmacology ; Cell Line, Tumor ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Oxidative Stress/drug effects ; Oxidative Stress/physiology ; PPAR gamma/physiology ; Parkinson Disease/metabolism ; Rosiglitazone ; Thiazolidinediones/pharmacology ; Thiazolidinediones/therapeutic use
مستخلص: Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to provide neuroprotection in a number of neurodegenerative diseases including Parkinson's disease and Alzheimer's disease. These protective effects are primarily considered to result from the anti-inflammatory actions of PPARγ, however, there is increasing evidence that anti-oxidant mechanisms may also contribute. This study explored the impact of the PPARγ agonist rosiglitazone and the PPARγ antagonist GW9662 in the MPP(+)/MPTP (1-methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease, focussing on oxidative stress mechanisms. Rosiglitazone attenuated reactive oxygen species formation induced by MPP(+) in SH-SY5Y cells concurrent with an upregulation of glutathione-S-transferase activity, but not superoxide dismutase activity. These responses were not attenuated by cotreatment with GW9662 suggesting that PPARγ activation is not required. The localisation of PPARγ in vivo to dopaminergic neurons of the substantia nigra pars compacta (SNpc) was established by immunohistochemistry and PPARγ levels were found to be upregulated 7 days after MPTP treatment. The importance of PPARγ in protecting against MPTP toxicity was confirmed by treating C57BL6 mice with GW9662. Treatment with GW9662 increased MPTP-induced neuronal loss in the SNpc whilst not affecting MPTP-induced reductions in striatal dopamine and 3,4-dihdroxyphenylacetic acid. GW9662 also caused neuronal loss in the SNpc of saline-treated mice. The evidence presented here supports the role of anti-oxidant mechanisms in the protective effects of PPARγ agonists in neurodegenerative diseases, but indicates that these effects may be independent of PPARγ activation. It also demonstrates the importance of PPARγ activity for neuronal survival within the SNpc.
(Copyright © 2012 Elsevier Inc. All rights reserved.)
التعليقات: Comment in: Exp Neurol. 2012 Dec;238(2):133-7. doi: 10.1016/j.expneurol.2012.08.012. (PMID: 23085103)
References: Mol Pharmacol. 2005 Dec;68(6):1782-92. (PMID: 16155208)
Neuroscience. 2011 Oct 27;194:250-61. (PMID: 21839812)
J Neurosci. 2009 May 13;29(19):6186-95. (PMID: 19439596)
Cell. 2010 Mar 19;140(6):918-34. (PMID: 20303880)
J Neurosci. 2008 Sep 10;28(37):9287-96. (PMID: 18784309)
Brain Res. 2006 Jun 22;1096(1):196-203. (PMID: 16725118)
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1977-82. (PMID: 17267597)
J Neurotrauma. 2011 Jun;28(6):983-93. (PMID: 21501066)
Toxicol In Vitro. 2011 Jun;25(4):839-47. (PMID: 21333731)
Mol Endocrinol. 2002 Dec;16(12):2793-801. (PMID: 12456800)
Cardiovasc Res. 2009 Jul 15;83(2):213-25. (PMID: 19447775)
Neurodegeneration. 1995 Sep;4(3):257-69. (PMID: 8581558)
Nat Protoc. 2007;2(1):141-51. (PMID: 17401348)
Biochem Biophys Res Commun. 2009 Feb 6;379(2):406-10. (PMID: 19109927)
Annu Rev Pharmacol Toxicol. 2005;45:51-88. (PMID: 15822171)
Endocr Rev. 1999 Oct;20(5):649-88. (PMID: 10529898)
J Neurosci. 2008 Mar 5;28(10):2471-84. (PMID: 18322092)
Neurobiol Aging. 1993 Jul-Aug;14(4):275-85. (PMID: 8367009)
J Neurol Sci. 2007 Feb 15;253(1-2):53-60. (PMID: 17266988)
Eur J Neurosci. 2000 Jul;12(7):2215-23. (PMID: 10947800)
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5473-8. (PMID: 12702778)
J Neuroimmunol. 2001 May 1;116(1):40-8. (PMID: 11311328)
J Neuroimmunol. 2005 Apr;161(1-2):113-22. (PMID: 15748950)
Biochem Biophys Res Commun. 2009 Jul 3;384(3):357-61. (PMID: 19422805)
Ann Neurol. 2003;53 Suppl 3:S26-36; discussion S36-8. (PMID: 12666096)
Nature. 1998 Jan 1;391(6662):79-82. (PMID: 9422508)
Biochem Pharmacol. 2001 Oct 15;62(8):1071-9. (PMID: 11597575)
Nature. 1998 Jan 1;391(6662):82-6. (PMID: 9422509)
Mol Cell. 1999 Oct;4(4):585-95. (PMID: 10549290)
J Neurochem. 2004 Jan;88(2):494-501. (PMID: 14690537)
J Neurosci. 2002 Mar 1;22(5):1763-71. (PMID: 11880505)
Ann Neurol. 2002 Jun;51(6):694-702. (PMID: 12112074)
Eur J Neurosci. 2009 Mar;29(5):954-63. (PMID: 19245367)
Br J Pharmacol. 2008 May;154(1):226-33. (PMID: 18332857)
Gene. 1999 Jun 24;234(1):87-91. (PMID: 10393242)
J Endocrinol. 2001 Jun;169(3):453-9. (PMID: 11375115)
Neurosci Lett. 2002 Jun 7;325(2):124-8. (PMID: 12044637)
Exp Neurol. 2005 Jun;193(2):279-90. (PMID: 15869932)
Neuron. 2003 Sep 11;39(6):889-909. (PMID: 12971891)
Cancer Res. 2004 May 15;64(10):3701-13. (PMID: 15150131)
Exp Neurol. 2005 Feb;191(2):331-6. (PMID: 15649489)
J Neurochem. 2002 Aug;82(3):615-24. (PMID: 12153485)
J Neuroimmunol. 2005 Oct;167(1-2):99-107. (PMID: 16091293)
Neurobiol Dis. 2008 Mar;29(3):422-37. (PMID: 18086530)
J Biol Chem. 2007 Dec 21;282(51):37006-15. (PMID: 17965419)
Nature. 1996 Nov 7;384(6604):39-43. (PMID: 8900274)
J Biol Chem. 2008 Sep 12;283(37):25628-25637. (PMID: 18640979)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; United Kingdom BB_ Biotechnology and Biological Sciences Research Council; WT080782MF United Kingdom WT_ Wellcome Trust
المشرفين على المادة: 0 (2-chloro-5-nitrobenzanilide)
0 (Anilides)
0 (Antioxidants)
0 (Neuroprotective Agents)
0 (PPAR gamma)
0 (Thiazolidinediones)
05V02F2KDG (Rosiglitazone)
تواريخ الأحداث: Date Created: 20120316 Date Completed: 20120628 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC3350857
DOI: 10.1016/j.expneurol.2012.02.017
PMID: 22417924
قاعدة البيانات: MEDLINE
الوصف
تدمد:1090-2430
DOI:10.1016/j.expneurol.2012.02.017